Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
Data updated
Research Footprint
Mathieu Seynaeve appears in 10 tracked papers (2020–2026), most studied alongside 5-MeO-DMT, Psilocybin and Placebo, across Safety & Risk Management, Depressive Disorders and Chronic Pain.
Most-cited paper: Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (1057 citations).
Frequent co-authors: James Rucker, Fiona Dunbar and Anna Ermakova.
Background & Research
Mathieu Seynaeve, MD, is a psychiatrist and psychedelic clinical researcher at Beckley Psytech. According to conference and company materials, he serves as Senior Medical Director and Head of Psychotherapy, where he has helped design clinical studies of 5-MeO-DMT and related psychotherapeutic support models. He previously worked in the Psychoactive Trials Group at the Centre for Affective Disorders, IoPPN, on placebo-controlled psilocybin trials, and is pursuing a PhD on psychological mechanisms of psychedelic psychotherapy.
Key Impact
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Collaboration Network
29 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Mathieu Seynaeve is associated with.
Beckley Psytech
Private BiotechBeckley Psytech was a clinical-stage biopharmaceutical company founded in 2019 as a spinout from the Beckley Foundation — the UK-based psychedelic research charity co-founded by Amanda Feilding. The company focused on developing novel proprietary psychedelic formulations, with its lead asset BPL-003, an intranasal formulation of 5-MeO-DMT (mebufotenin benzoate) for treatment-resistant depression. BPL-003 received FDA Breakthrough Therapy Designation and delivered positive Phase 2b results. In November 2025, Beckley Psytech merged with atai Life Sciences in an all-share transaction to form AtaiBeckley, with BPL-003 becoming the lead asset of the combined company.
View stakeholder →South London and Maudsley NHS Foundation Trust
South London and Maudsley NHS Foundation Trust (SLaM) is the UK's leading academic mental health Trust, home to Maudsley Hospital and the NIHR Maudsley Biomedical Research Centre; in partnership with COMPASS Pathways and King's College London's Institute of Psychiatry, it has established a dedicated Psychedelics and Mental Health Research Centre conducting psilocybin Phase 3 trials for treatment-resistant depression, MDMA therapy for PTSD, 5-MeO-DMT studies, and the SIGNATURE synaptic imaging biomarker trial, aiming to treat 650–700 patients over five years.
View stakeholder →